TriangleHEALTH PROFESSIONAL · SOURCE READING
FLT3 Variants
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Molecular Variants and Therapeutic Impact
FLT3 variants (either internal tandem duplication or tyrosine kinase domain variants) are observed in 40% to 50% of APL cases. The presence of FLT3 variants is correlated with higher white blood cell counts and the microgranular variant (M3v) subtype.[19-23] The FLT3 variant has previously been associated with an increased risk of induction death and, in some reports, an increased risk of treatment failure.[19-25] Given the extremely high cure rates for children with APL who were treated with tretinoin and arsenic trioxide, FLT3 variants are not associated with inferior outcomes.[26]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice